Raltegravir Plus Abacavir/Lamivudine: Effective HIV-1 Switch Therapy in Virologically Suppressed Patients
Raltegravir combined with abacavir/lamivudine is a safe and well tolerated switching strategy for patients with stable HIV-1 infection
Investigators examine whether same-day ART initiation was associated with better engagement in care and viral suppression in HIV+ women starting therapy during pregnancy.
Implementation of an electronic health record automatically linking HIV/hepatitis C virus screening to laboratory ordering for adult patients was found to be more effective than a nurse-driven protocol.
The strongest survival prognostic factor in HCC with co-infection of HIV and HCV is radiological aggressiveness of the tumor.